WHO recommends Epclusa, a Hepatitis C Combined Therapy in Just One Pill
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by admin
3y ago
A combined treatment for hepatitis C based on sofosbuvir and velpatasvir (brand name Epclusa) is among the additions to the World Health Organization (WHO) Model List of Essential Medicines (EML) for 2017. Velpatasvir is an antiviral drug that inhibits a viral protein called NS5A. This drug prevents the replication of the virus and the assembly of new virus particles. Sofosbuvir, which already was included in the previous EML, targets another protein in the hepatitis C virus (HCV), the HCV NS5B polymerase, which also is essential for viral replication. Several clinical trials showe ..read more
Visit website
Sofosbuvir Reduces Transplant Need and Mortality Rates in Hepatitis C Patients, Study Finds
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Daniela Semedo, PhD
3y ago
Sofosbuvir (sold under the brand name Sovaldi from Gilead Sciences, among others) significantly reduces the risk of death and the need for liver transplant in patients with hepatitis C who suffer from advanced stages of liver disease. Researchers at Intermountain Healthcare’s Intermountain Medical Center in Salt Lake City studied almost 1,900 patients with hepatitis C and found that the number of patients needing a liver transplant was reduced by 40 percent after they were treated with sofosbuvir. The study results were recently presented at the 2017 International Joint C ..read more
Visit website
Survey Reports Gaps in Hepatitis Testing and Monitoring Across European Union
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Carolina Henriques
3y ago
Results from a European Centre for Disease Prevention and Control (ECDC) survey suggest that European Union/European Economic Area (EU/EEA) member states suffer from significant gaps in national testing policies and practices when it comes to hepatitis B and hepatitis C. Survey respondents specifically identified the need for Europe-wide practical guidance on testing practice, evaluation, and monitoring, according to a press release. The ECDC estimates that between nine and 10 million citizens in the EU/EEA live with the hepatitis B virus (HBV) or hepatitis C virus (HCV), with many being una ..read more
Visit website
FDA Reviewing Application for Opdivo Use in Hepatocellular Carcinoma, Often Caused by Hepatitis
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by admin
3y ago
The U.S. Food and Drug Administration (FDA) recently accepted a supplemental Biologics License Application (sBLA) to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC). People chronically infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) are at increased risk of developing HCC. The FDA set an action date of Sept. 24, 2017, for a final decision on the application. “We believe the FDA acceptance of our application for Opdivo with priority review status is an important recognition of the significant unmet need for patients wi ..read more
Visit website
Graphene Sensor Device Under Development to Provide Low-Cost Diagnosis of Multiple Hepatitis Types
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Charles Moore
3y ago
Researchers in the U.K. and China are collaborating on the development of a low-cost, noninvasive electronic sensor device to simultaneously test for three types of hepatitis. The technology uses graphene, a one-atom thick, two-dimensional material with high electrical and heat conductivity. Ultralight and flexible but 200 times stronger than steel, graphene was first isolated in 2004 by two researchers at the University of Manchester. Professors Andre Geim and Kostya Novoselov were awarded the 2010 Nobel Prize in physics for their achievements with graphene. Th ..read more
Visit website
17 US States’ High Hepatitis C Rates Are a Result of Public Policy Shortcomings, Report Says
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Alice Melão
3y ago
Seventeen American states had high rates of Hepatitis C in 2015 because they lacked laws and Medicaid policies to prevent drug users from developing the disease, and obtaining treatment once they did, according to a U.S. government report. Those who inject drugs are the segment of the population most susceptible to the disease, also known as HCV, many studies have shown. A key reason they are prone to it is that many share contaminated needles with other users. The report connecting public policy to the high levels of HCV in the 17 states is entitled “State HCV Incidence and Policies Related ..read more
Visit website
Patient-Centered Medical Home Care Approach Effective in Hepatitis C Treatment
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Carolina Henriques
3y ago
Boston Medical Center eliminated the hepatitis C virus (HCV) in 66 patients it treated with a comprehensive care program that included doctors, pharmacists, pharmacy techs and social workers, according to a study. The doctors were general practitioners, so a key conclusion of the research was that primary care providers could deliver HCV treatment as well as specialists. The center’s Adult Primary Care Practice used what it called the patient-centered medical home model of care to treat the patients between March 2015 and April of 2016. The word “home” does not ..read more
Visit website
Hepatitis C Hijacks Signaling-Pathway Proteins to Survive, Grow in the Body, Study Reports
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Alice Melão
3y ago
The hepatitis C virus hijacks proteins involved in key signaling pathways to help it survive and grow in the body, according to Australian researchers who identified the proteins. New treatments for HCV could evolve from the findings, the team said. The virus is a serious disease that can lead to major liver problems, including hepatitis, cirrhosis and cancer. A team from Monash University’s Biomedicine Discovery Institute spearheaded the study, titled “Signalome-wide assessment of host cell response to hepatitis C virus.” It was published in the journal Nature Commu ..read more
Visit website
Newly Diagnosed Cases of Hepatitis Delta Virus Infection in US is Increasing
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Daniela Semedo, PhD
3y ago
The number of people newly diagnosed with Hepatitis Delta virus (HDV) infection in the United States is increasing. Furthermore, the incidence of HDV co-infection among chronic Hepatitis B virus (HBV) patients also is rising nationwide. These alarming conclusions come from data from an International Classification of Diseases (ICD) analysis presented by Eiger BioPharmaceuticals at the 2017 Digestive Disease Week, held in Chicago, Illinois, May 6-9. “Hepatitis Delta is the most aggressive form of viral hepatitis, and due to the absence of an approved therapy, testing for hepatitis delta ..read more
Visit website
Eiger Files New Drug Application for Lambda as Hepatitis D Therapy, Starts Clinical Trials
Hepatitis News Today | The Web's Daily Resource for Hepatitis News
by Carolina Henriques
3y ago
Eiger BioPharmaceuticals has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for Lambda (pegylated interferon lambda 1a) as a treatment for the hepatitis delta virus (HDV). In addition, a series of clinical trial sites worldwide have started enrolling patients for a Phase 2 LIMT open-label trial (NCT02765802) evaluating 120- or 180-microgram injections of Lambda to treat chronic HDV infection. HDV is also known as hepatitis D. The therapy will be administered weekly for 48 weeks in 30 to 40 patients with chronic HDV. After the 48 week ..read more
Visit website

Follow Hepatitis News Today | The Web's Daily Resource for Hepatitis News on FeedSpot

Continue with Google
Continue with Apple
OR